Formosa Pharmaceuticals, Inc. (TPE:6838)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
27.80
-0.10 (-0.36%)
At close: Apr 29, 2026
16.81%
Market Cap 4.21B
Revenue (ttm) 9.50M
Net Income (ttm) -83.57M
Shares Out 150.98M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,860
Average Volume 505,498
Open 28.30
Previous Close 27.90
Day's Range 27.75 - 28.35
52-Week Range 24.10 - 43.45
Beta 0.85
RSI 45.15
Earnings Date May 8, 2026

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and color... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6838
Full Company Profile

Financial Performance

In 2025, Formosa Pharmaceuticals's revenue was 9.50 million, a decrease of -93.38% compared to the previous year's 143.36 million. Losses were -83.57 million, -58.43% less than in 2024.

Financial Statements

News

There is no news available yet.